Prediction on liver fibrosis using different APRI thresholds when patient age is a categorical marker in patients with chronic hepatitis B
Authors:
- Hong-Bo LiuHLHong-Bo Liu
- Jian-Ping ZhouJZJian-Ping Zhou
- Yong ZhangYZYong Zhang
- Xiao-Hui LvXLXiao-Hui Lv
- Wei WangWWWei Wang
- 1 January 2011
- journal article
- Published by Elsevier in Clinica Chimica Acta
- Vol. 412 (1-2) , 33-37
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- FibroTest-ActiTest as a non-invasive marker of liver fibrosisGastroentérologie Clinique Et Biologique, 2008
- Natural history of chronic hepatitis B: Special emphasis on disease progression and prognostic factorsJournal of Hepatology, 2008
- The Natural History and Treatment of Chronic Hepatitis B: A Critical Evaluation of Standard Treatment Criteria and End PointsAnnals of Internal Medicine, 2007
- Serology based disease status of Pakistani population infected with Hepatitis B virusBMC Infectious Diseases, 2007
- Sequential algorithms combining non-invasive markers and biopsy for the assessment of liver fibrosis in chronic hepatitis BWorld Journal of Gastroenterology, 2007
- Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measuresJournal of Viral Hepatitis, 2004
- Histological outcome during long-term lamivudine therapyGastroenterology, 2003
- Liver BiopsyNew England Journal of Medicine, 2001
- The Role of Liver Biopsy in Chronic Hepatitis CHepatology, 2001
- Complications following percutaneous liver biopsyJournal of Hepatology, 1986